355 reports of this reaction
1.8% of all LANREOTIDE ACETATE reports
#13 most reported adverse reaction
INJECTION SITE MASS is the #13 most commonly reported adverse reaction for LANREOTIDE ACETATE, manufactured by Ipsen Biopharmaceuticals, Inc.. There are 355 FDA adverse event reports linking LANREOTIDE ACETATE to INJECTION SITE MASS. This represents approximately 1.8% of all 20,256 adverse event reports for this drug.
Patients taking LANREOTIDE ACETATE who experience injection site mass should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE MASS is a less commonly reported adverse event for LANREOTIDE ACETATE, but still significant enough to appear in the safety profile.
In addition to injection site mass, the following adverse reactions have been reported for LANREOTIDE ACETATE:
The following drugs have also been linked to injection site mass in FDA adverse event reports:
INJECTION SITE MASS has been reported as an adverse event in 355 FDA reports for LANREOTIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE MASS accounts for approximately 1.8% of all adverse event reports for LANREOTIDE ACETATE, making it a notable side effect.
If you experience injection site mass while taking LANREOTIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.